Results 261 to 270 of about 2,243,647 (283)
Some of the next articles are maybe not open access.
Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer
Oncology, 200024 patients were enrolled into a phase I–II study conducted to determine the maximum tolerated doses of topotecan-gemcitabine in sequential combination and the response rate in platinum/paclitaxel resistant ovarian cancer patients. A total of 83 courses are evaluable, with a median number of three cycles administered per patients (range 2–7). Topotecan
S, Greggi +7 more
openaire +2 more sources
Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis.
Anticancer research, 2004The T-cell lymphoma cell line HuT78B1, selected for resistance to Fas-mediated apoptosis, resulted unexpectedly resistant to the apoptotic and cytotoxic effects of gemcitabine (dFdC). We investigated whether this resistance was due to the impairment of the Fas/Fas-ligand (FasL) system.dFdC effects were studied in HuT78B1 and in the parental Fas ...
MELI, Maria +8 more
openaire +4 more sources
Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma
International Journal of Gynecological Cancer, 2005Platinum compounds are the key components of chemotherapy for ovarian cancer. Preclinical models in an ovarian cancer cell line (A2780) have demonstrated synergistic activity when gemcitabine is added to cisplatin compared with either single agent alone.
openaire +2 more sources
Gemcitabine in cisplatin-resistant ovarian cancer.
Seminars in oncology, 1996Many new drugs have been tested in phase II studies in recent years. With a number of drugs the results vary because of differences in the patients recruited to these studies. A number of factors impact the response to second-line therapy, including the treatment-free interval between the end of previous therapy and the entry into phase II study, the ...
B, Lund, J P, Neijt
openaire +1 more source
Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma
Anticancer ResearchChemotherapy resistance is an important problem in the treatment of patients with cholangiocarcinoma (CCA) who are not eligible for surgery. This study aimed to overcome gemcitabine (Gem) resistance in CCA by investigating and targeting Gem resistance-associated molecules.Three stable Gem-resistant CCA cell lines (CCA-GemR) were established by ...
Sonexai, Kidoikhammouan +6 more
openaire +2 more sources
Pancreas, 2014
Gemcitabine resistance (GR) is one of the critical issues for therapy for pancreatic cancer, but the mechanism still remains unclear. Our aim was to increase the understanding of GR by metabolic profiling approach.To establish GR cells, 2 human pancreatic cancer cell lines, SUIT-2 and CAPAN-1, were exposed to increasing concentration of gemcitabine ...
Yoshinori, Fujimura +10 more
openaire +2 more sources
Gemcitabine resistance (GR) is one of the critical issues for therapy for pancreatic cancer, but the mechanism still remains unclear. Our aim was to increase the understanding of GR by metabolic profiling approach.To establish GR cells, 2 human pancreatic cancer cell lines, SUIT-2 and CAPAN-1, were exposed to increasing concentration of gemcitabine ...
Yoshinori, Fujimura +10 more
openaire +2 more sources
Gemcitabine in Multi-Resistant Non-Hodgkin Lymphomas
Tumori Journal, 2004Enric Carcereny +2 more
openaire +2 more sources
The effect of HBE1 on resistance to gemcitabine in pancreatic cancer cells
Arab Journal of GastroenterologyChemotherapy resistance remains a major challenge in pancreatic cancer treatment, with gemcitabine-based therapy being a primary approach. However, the mechanisms underlying gemcitabine resistance in pancreatic cancer cells are not yet fully understood.
Jiyun, Cheng +7 more
openaire +2 more sources
Pancreatic Cancer Resistance to Gemcitabine
2019P.S. Sushma, Ganji Purnachandra Nagaraju
openaire +1 more source